Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Censa Pharmaceuticals acquisition diversifies and strengthens PTC 's portfolio of rare disorders by adding the lead orphan metabolic disease drug, CNSA-001.
Lead Product(s): Sepiapterin
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PTC Therapeutics
Deal Size: $366.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition May 06, 2020